These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37668815)

  • 1. Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study.
    Mitani S; Kito Y; Hino K; Kawakami K; Izawa N; Hanamura F; Yamamoto Y; Shoji H; Komori A; Boku S; Tsuchihashi K; Kato K; Nonagase Y; Matsumoto T; Furuta M; Kawakami H
    Target Oncol; 2023 Sep; 18(5):707-715. PubMed ID: 37668815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
    Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
    Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
    Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
    BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Induction Management in Patients With Left-Sided
    Parisi A; Cortellini A; Venditti O; Filippi R; Salvatore L; Tortora G; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Fulgenzi C; Lombardi P; Roselló Keränen S; Depetris I; Giampieri R; Morelli C; Di Marino P; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Patruno L; D'Orazio C; Ficorella C; Ferri C; Porzio G
    Front Oncol; 2021; 11():712053. PubMed ID: 34778029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting.
    Siegelmann-Danieli N; Farkash A; Katzir I; Vesterman Landes J; Rotem Rabinovich H; Lomnicky Y; Carmeli B; Parush-Shear-Yashuv N
    PLoS One; 2016; 11(5):e0154689. PubMed ID: 27144545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study.
    Rosati G; Corsi D; Avallone A; Brugnatelli S; Dell'Aquila E; Cinausero M; Aprile G; Cicero G; Carlomagno C; Colombo A; Rapisardi S; Pinto C; Reggiardo G; Bilancia D
    J Geriatr Oncol; 2022 Apr; 13(3):302-307. PubMed ID: 34716122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
    Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
    Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world first-line treatment of patients with BRAF
    Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D
    ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer.
    Amonkar MM; Chase M; Myer NM; Wang T; Turzhitsky V; Spira A
    Cancer Treat Res Commun; 2023; 36():100712. PubMed ID: 37301728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
    Roset M; Amonkar M; Patel R; Lara N; Kothari S
    Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
    Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options after regorafenib failure in metastatic colorectal cancer.
    Eraslan E; Doğan M; Yildiz F; İlhan A; Öksüzoğlu ÖB
    Eur Rev Med Pharmacol Sci; 2021 May; 25(9):3470-3477. PubMed ID: 34002820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer.
    Yang Q; Huang Y; Jiang Z; Wang H; Li W; Zhang B; Xie D
    Onco Targets Ther; 2018; 11():2467-2473. PubMed ID: 29760556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.
    Archwamety A; Teeyapun N; Siripoon T; Poungvarin N; Tanasanvimon S; Sirachainan E; Akewanlop C; Korphaisarn K
    Front Oncol; 2022; 12():813009. PubMed ID: 35242708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.
    Jácome AA; Kee B; Fogelman D; Dasari A; Shureiqi I; Raghav K; Morris V; Johnson B; Overman M; Wolff R; Kopetz S; Rogers J; Ahmed SU; Mehdizadeh A; Rothschild N; Eng C
    Clin Colorectal Cancer; 2020 Dec; 19(4):248-255.e6. PubMed ID: 32665092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
    Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
    Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Comparative Analysis of KRAS G12C
    Giampieri R; Lupi A; Ziranu P; Bittoni A; Pretta A; Pecci F; Persano M; Giglio E; Copparoni C; Crocetti S; Mandolesi A; Faa G; Coni P; Scartozzi M; Berardi R
    Front Oncol; 2021; 11():736104. PubMed ID: 34660299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
    Dijksterhuis WPM; Verhoeven RHA; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Int J Cancer; 2020 Apr; 146(7):1889-1901. PubMed ID: 31340065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Deepness of Response' Is Associated with Overall Survival in Standard Systemic Chemotherapy for Metastatic Colorectal Cancer.
    Nozawa H; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Hata K; Kazama S; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Watanabe T
    Chemotherapy; 2014; 60(5-6):360-7. PubMed ID: 26389969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.